Resources

In part 1 of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the various weight loss conditions a patient may experience and the medications that can help.

In part 2 of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the practitioner coverage available to the patients of his practice.

In part 3 of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the most effective exercises and best method for patients who want to monitor their weight loss.

In part 4 of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the success of the geriatric patient with diabetes who needs to lose weight.

In part 5 of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about his philosophy for treating patients and what he's wants healthcare providers to take away from his presentation.

In part 6, the conclusion of this Exclusive Interview, Dr. Ken Fujioka talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the potential treatments in development for weight issues and the growth of the discussion among today's healthcare providers.

Woman, 67 years of age, type 2 diabetes for 22 years, class II obesity. Has recently been managing her glucose levels with weight loss, using Tresiba, Trulicity, and metformin. Recent A1C 6.5%, which she’s worked hard for and been extremely proud of. She hasn’t had numbers like she has recently had for years.

In part 5 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the cost of PCSK9 inhibitors in the U.S. versus Europe.

In this week's Homerun Slides, understanding insulin resistance issues.

Dyslipidemia: The relationship between cholesterol and cancer risk has been difficult to discern from epidemiologic studies. Individuals with the metabolic syndrome and T2DM frequently have a dyslipidemic profile with elevated triglycerides and decreased high-density lipoprotein cholesterol (HDL-C). In the Metabolic Syndrome Cancer (Me-Can) European cohort elevated triglyceride levels were associated with colon, respiratory, kidney, thyroid cancers, and melanoma in men and respiratory, cervical, and nonmelanoma skin cancers in women.